Abstract
Aim:
Vitamin D deficiency is very common among children with IBD. Since there are conflicting results regarding the association of vitamin D with IBD, we conducted this systematic review to confirm the association of vitamin D with IBD.
Methods:
We conducted a systematic search in Scopus, Cochrane Library, Web of Science, PubMed, and Google Scholar to find relevant studies. Articles with cross-sectional and case-control designs that reported the association between vitamin D and IBD among children were included.
Results:
Eventually, 9 studies (with 16 effect sizes) reported the mean and SD or the median and the interquartile range of serum vitamin D levels in both subjects with IBD and control subjects. The random effects meta-analysis revealed that subjects with IBD had −1.159 ng/ml (95% CI: −2.783, 0.464) lower serum vitamin D concentrations compared with their healthy counterparts, but this difference was not significant. A total of 14 studies (with 18 effect sizes) with 2,602 participants provided information for the prevalence of vitamin D deficiency or insufficiency in patients with IBD as 44% (95% CI: 0.34–0.54) with significant heterogeneity noted among studies (p < 0.001; I2 = 97.31%).
Conclusion:
This systematic and meta-analysis study revealed that vitamin D deficiency was associated with IBD. Longitudinal studies should be conducted in the future to confirm our findings. Large randomized controlled trials assessing the doses of supplementation of vitamin D would provide a better understanding of the association between vitamin D and IBD.
Introduction
Inflammatory bowel disease (IBD) includes both ulcerative colitis (UC) and Crohn's disease (CD). IBD is a systemic, chronic disease. UC is confined to the rectum and/or the colon, whereas CD involves the entire gastrointestinal tract, with the most common occurrence in the ileum and the colon (1). Overall, the pediatric prevalence of IBD increased by 133% from 2007 to 2016 in the United States, and the subgroup of children aged 10–17 years was the major contributor to the rising pediatric IBD prevalence (2). IBD presents differently in adults and children. For example, CD is more prevalent in pediatrics when compared to UC. This is completely different from that of adult IBD (3). Even among the two age groups, the disease characteristics differ. The complications are more in pediatric IBD compared to adults (4).
The exact etiology of IBD may be attributed to changes in the intestinal flora, residing in urban areas, and diets having high amounts of fats and carbohydrates (5). Various studies reported the role of vitamin D in IBD (6, 7). Vitamin D deficiency may lead to a reduction in bacterial clearance in the colon (8). This vitamin changes the immune responses by influencing macrophages and T lymphocytes, hence avoiding excessive immune responses, and also repairs the intestinal mucosal barrier (9, 10).
Low vitamin D levels are more common in patients with IBD (11). However, it is not specific whether low vitamin D levels are related to malabsorption due to damage in the intestinal mucosa (12). Some observational studies reported low vitamin levels in patients with IBD (13, 14), and some studies reported a lack of decrease in vitamin D levels (15, 16). Vitamin D deficiency is very common among children with CD. Even osteoporosis and growth retardation are commonly noticed in CD when compared to UC (17). Similar to our study, a study was conducted previously by Del Pinto et al. (18) in 2015, considering all age groups. However, focusing on the age group of children and adolescents is necessary due to their critical age for growth and development. In addition, no significant results were obtained in that subgroup analysis due to the limitations of studies related to children and adolescents. Since there is no clear evidence of a direct association between vitamin D and IBD among children and adolescents, we conducted this systematic review to confirm the association of vitamin D with IBD.
Materials and methods
In this systematic review and meta-analysis, we investigated the data extracted based on components of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (19) and MOOSE (Meta-Analyses of Observational Studies in Epidemiology) checklist (20) on the relationship between serum vitamin D and inflammatory bowel disease in pediatric patients.
Search strategy and selection process
A structural and comprehensive literature was accomplished based on articles published up to 20 February (year) in the following electronic databases: Scopus, Cochrane Library, Web of Science, PubMed, and Google Scholar. The search used the terms “vitamin D,” “ergocalciferol,” “inflammatory bowel disease,” “Crohn's disease,” and “ulcerative colitis” in several combinations. The full electronic search strategy is reported in Supplementary Table 1. There were no date or language restrictions on imported articles. Moreover, all clinical trial and review article references were checked to find any relevant studies. After deleting duplicate articles, the title and abstract screening processes were performed. Subsequently, two researchers studied the full-text papers independently to find all the obligatory data for meta-analysis. The third researcher was called to resolve any discrepancies. Only articles that met the following criteria were included in this meta-analysis:
a) Observational studies—either case-control, cross-sectional, or cohort designs,
b) Studies with adolescents or children (age < 18 years),
c) Articles that showed mean and standard deviation (SD) or prevalence of insufficiency or deficiency of serum vitamin D levels in patients with IBD (Crohn's disease or ulcerative colitis).
Papers with (1) randomized clinical trial designs, (2) animal-based studies, (3) gray literature (chapters of books, abstracts in conferences, or review articles), (4) adult patients, (5) athletics, and (6) assessment of IBD in the acute phase were excluded from the analysis.
Data extraction and syntheses
Required information of the eligible papers was extracted by two observers, such as the author's last name, publication date, the study location, study design, mean age of cases and controls, the number of cases and controls, type of study population (UC or CD), mean and SD of vitamin D concentration in patients and healthy participants or prevalence of vitamin D deficiency or insufficiency status, seasonally matching or adjusting, and method of vitamin D assessment.
Quality assessments
The quality of the chosen papers in this meta-analysis was assessed using the Newcastle-Ottawa scale (21), which included 9 questions in three main sections such as selection of participants (0–4 points), comparability between groups (0–3 points), and outcome assessment (0–3 points). The quality evaluation process was reviewed by two investigators, and any differences in scoring were resolved by consensus.
Statistical analyses
All data analyses were performed using the Stata 13 software (Stata Corp., College Station, Texas, USA). Data on vitamin D levels in patients with IBD in case-control studies were reported as weighted mean differences and SD or prevalence of deficiency or insufficiency in cross-sectional articles. The studies were conducted in different populations and countries, so the random-effects analysis was used to control variation. To determine the heterogeneity, the I-square (I2) index was assessed by random-effects analysis, and high heterogeneity was described if I2 was more than 50%. A sensitivity analysis was conducted to find out which study had the highest proportion in the pool effect size. Afterward, Egger's regression model was used to examine the publication bias in the funnel plots. Due to the high heterogeneity between records, we decided to carry out the subgroup analysis to distinguish the possible reasons for high heterogeneity and the effect of variant agents on the relationship between serum levels of vitamin D and IBD. These subgroups were based on assessing vitamin D methods such as HPLC (high-performance liquid chromatography), RIA (radioimmunoassay), and chemiluminescence-based competitive protein-binding assay and evaluating matching the season to vitamin D concentration (yes, matched; NR, not reported).
Literature review
The main characteristics of case-control and cross-sectional studies are presented in Table 1 and Figure 1. Approximately 3,564 articles were searched electronically; 1,579 duplicate items were removed in the screening process, and 1,936 articles were eliminated as they had no relation to the purpose of the study. In addition, 14 articles did not meet the qualitative and quantitative criteria given in this study. Notably, a related cohort study was identified, which was omitted due to the format of the analysis, so we described it in the discussion part. Eventually, 9 articles (16 effect sizes) with a case-control design declared the concentration of vitamin D in children with a mean (SD), and 14 studies (with 18 effect sizes) declared the prevalence of vitamin D deficiency or insufficiency in pediatrics. These studies were published between 2003 and 2019, and most of the records (n = 11) were conducted in the United States (22, 25, 29–31, 33–36, 38, 39, 42, 43) and the rest in Canada (23, 40), Australia (32), Finland (24), Denmark (26), Italy (28), South Korea (27, 41), and Israel (37). In general, we entered data of 4,803 children participants with an age range of 2–18 years. Based on the methodological assay, the quality score was at least 6 points for the articles, and the majority gained high-quality points. Notably, the vitamin D measurement seasons were different in the studies, and some did not report any data, and some case-control studies presented season matching or adjustment. In addition, various measurement methods have been applied; some studies used HPLC (high-performance liquid chromatography) (24, 43) or RIA (radioimmunoassay) (29) and others applied chemiluminescence-based competitive protein-binding assays (23, 28, 30, 32, 35, 36, 39, 44) to measure the concentration of vitamin D.
Table 1
| No | References | Country | Study Design | Population of study | Mean age, y | Total N | N case | Mean/ sdcase (ng/ml) | N control | Mean/sd control (ng/ml) | Deficiency or insufficiency status | Season adjust/ matching | Season of measurement | Q | Method of vitamin D assessing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nwosu (22) | USA | Case-control | CD | 8.5 | 25 | 28.24+10.28 | 49 | 26.16 + 10.44 | NR/yes | Winter + spring,14/25 (56) | DiaSorin Liaison | |||
| 2 | El-Matary et al., (23) | Canada | Case-control | CD | 12.2 | 39 | 26.68 + 10.2 | 56 | 32.68 + 6.16 | NR/yes | NR | Protein binding assay after column chromatography (Esoterix | |||
| 3 | El-Matary et al. (23) | Canada | Case-control | UC | 12.2 | 21 | 22.76 + 8.8 | 56 | 32.68 + 6.16 | NR/yes | NR | ||||
| 4 | Laakso et al. (24) | Finland | Case-control | IBD | 14.9 | 80 | 21.6 + 25.48 | 80 | 18.5 + 19.25 | NR/ NR | NR | (HPLC) | |||
| 5 | Alkhouri et al. (15) | USA | Case-control | CD | 12.3 | 46 | 29.9 + 12.7 | 61 | 26.7 + 9.4 | NR/ NR | Is less vitamin D deficiency in the summer months as compared with | (HPLC) | |||
| 6 | Alkhouri et al. (15) | USA | Case-control | UC | 12.3 | 12 | 32 + 25.8 | 61 | 26.7 + 9.4 | NR/ NR | Spring (P0.08), autumn (P0.15), and winter (P0.08). | ||||
| 7 | Alkhouri et al. (15) | USA | Case-control | ID | 12.3 | 3 | 21.7 + 7.5 | 61 | 26.7 + 9.4 | NR/ NR | Spring (P0.08), autumn (P0.15), and winter (P0.08). | ||||
| 8 | Prosnitz (Black participants) (25 ) | USA | Case-control | CD | 13.5 | 8 | 10.5 + 4.6 | 62 | 15.8 + 7.9 | Radioimmunoassay (RIA) with I125-labeled tracer | |||||
| 9 | Prosnitz (Non-black participants) (25) | USA | Case-control | CD | 13.5 | 70 | 23.5 + 0.2 | 159 | 25.3 + 8.7 | Yes/NR | Winter | ||||
| 10 | Veit et al. (16) | USA | Case-control | IBD | 16.4 Control (14.6) | 58 | 24 + 10.24 | 116 | 24 + 10.88 | Yes/yes | Summer–fall, %:57.6 | DiaSorin Liaison | |||
| 11 | Thorsen et al. (26) | Denmark | Case-control | CD | 14 | 155 | 11.2 + 6.54 | 384 | 10.68 + 6.9 | NR/Yes | All | Liquid chromatography mass spectrometry (LC-MS) | |||
| 12 | Thorsen et al. (26) | Denmark | Case-control | UC | 15 | 210 | 10.92 + 7.08 | 384 | 10.68 + 6.9 | NR/Yes | All | ||||
| 13 | Thorsen et al. (26) | Denmark | Case-control | IC | 11 | 19 | 12.72 + 8.68 | 384 | 10.68 + 6.9 | NR/Yes | All | ||||
| 14 | Sohn et al. (27) | Korea | Case-control | CD | 14.4 | 43 | 16.3 + 9.3 | 45 | 16.5 + 5.3 | NR/NR | NR | Liquid chromatography mass spectrometry (LC-MS) | |||
| 15 | Sohn et al. (27) | Korea | Case-control | UC | 14.4 | 17 | 19.9 + 7.2 | 45 | 16.5 + 5.3 | NR/NR | NR | ||||
| 16 | Strisciuglio et al. (28) | Italy | Case-control | IBD | 11 (Control: 9.4) | 33 | 19.2 + 9.7 | 18 | 28.2 + 12.1 | NR/Yes | Winter-spring | Enzyme-linked immunosorbent | |||
| 17 | Sentongo et al. (29) | Philadelphia | Cross-sectional | CD | 15.76 | 113 | 16% < 20 ng/ml Hypovitaminosis < 38 nmol/L. | Radioimmunoassay with a radioiodinated tracer | |||||||
| 18 | Pappa et al. (30) | USA | Cross-sectional | IBD | 15.76 | 130 | 34.6% < 15 ng/ml 10.8%: 25OHD ≤ 8 | Nichols Advantage chemiluminescence-based competitive protein-binding assay (Nichols Institute Diagnostics,San Clemente, CA | |||||||
| 19 | Pappa et al. (30) | USA | Cross-sectional | CD | 15.76 | 94 | 38.3% < 15 ng/ml 12.8%: 25OHD ≤ 8 | Nichols Advantage chemiluminescence-based competitive protein-binding assay (Nichols Institute Diagnostics,San Clemente, CA | |||||||
| 20 | Pappa et al. (30) | USA | Cross-sectional | UC | 15.76 | 36 | 25% < 15 ng/ml 5.6 %: 25OHD ≤ 8 | Nichols Advantage chemiluminescence-based competitive protein-binding assay (Nichols Institute Diagnostics,San Clemente, CA | |||||||
| 21 | Salehi et al. (31) | USA | Cross-sectional | IBD | NR | 110 | 63.6% < 20 ng/ml < 50 nmol/l | NR | |||||||
| 22 | Levin et al. (32) | Australia | Cross-sectional | IBD | 12.6 | 263 | 19: 20–30 ng/ml 51–75 nmol/l | Antibody-based chemiluminescence assay | |||||||
| 23 | Levin et al. (32) | Australia | Cross-sectional | IBD | 12.6 | 263 | 38 < 20 ng/ml Defficiency < 51 nmol/l | Antibody-based chemiluminescence assay | |||||||
| 24 | Goldberg et al. (33) | USA | Cross-sectional | UC | 2-21 | 24 | 80 < 20 ng/ml Insufficiency 20–30 nmol/L | NR | |||||||
| 25 | Goldberg et al. (33) | USA | Cross-sectional | CD | 2-21 | 52 | 60 < 20 ng/ml Insufficiency 20–30 nmol/L | NR | |||||||
| 26 | Schaefer et al. (34) | USA | Cross-sectional | IBD | NR | 92 | < 30 ng/mL < 30 ng/mL | NR | |||||||
| 27 | Syed et al. (35) | USA | Cross-sectional | IBD | 5-18.9 | 69 | 77 20–30 ng/ml Insufficiency < 30 ng/mL | Automated chemiluminescent technique (Automated IDS-iSYS System, Immunodiagnostic Systems, Fountain Hills, AZ) | |||||||
| 28 | Syed et al. (36) | USA | Cross-sectional | IBD | 5-18.9 | 69 | 38 < 20 ng/ml Deficiency < 20 ng/ml | Automated chemiluminescent technique (Automated IDS-iSYS System, Immunodiagnostic Systems, Fountain Hills, AZ) | |||||||
| 29 | Brandvayman et al. (37) | Israeil | Cross-sectional | IBD | 14 | 623 | 21 < 20 ng/ml defficiency | NR | |||||||
| 30 | Winter et al. (38) | USA | Cross-sectional | IBD | 203 | 31 < 20 ng/ml LOW < 9 ng/ml | NR | ||||||||
| 31 | Sauer et al. (39) | USA | Cross-sectional | UC | 12.7 | 388 | 57 20–30 ng/ml insufficient < 30 ng/Ml | IDS-iSYS 25-Hydroxyvitamin D automated chemiluminescense immunoassay (Gaithersburg, MD) | |||||||
| 32 | Mager et al. (40) | Canada | Cross-sectional | CD | NR | 102 | 56.80% 20–30 ng/ml insufficiency < 50 nmol/l | Liquid chromatogrpahy-mass spectroscopy (LC-MS) technology | |||||||
| 33 | Mager et al. (40) | Canada | Cross-sectional | UC | NR | 63 | 43.20% 20–30 ng/ml insufficiency < 50 nmol/l | Liquid chromatogrpahy-mass spectroscopy (LC-MS) technology | |||||||
| 34 | Kim et al. (41) | Korea | Cross-sectional | IBD | 13.1 | 96 | 56.80% 20–30 ng/ml insufficiency < 50 nmol/l | Liquid chromatogrpahy-mass spectroscopy (LC-MS) technology |
Characteristics of studies.
Figure 1
Flow chart of the included studies, including identification, screening, eligibility and the final sample included.
Meta-analysis
Eventually, 16 studies reported the mean and SD or median and interquartile range of serum vitamin D levels in both IBD and control subjects. The random effects meta-analysis revealed that subjects with IBD had −1.159 ng/ml (95% CI: −2.783, 0.464) lower serum vitamin D concentrations compared with their healthy counterparts, but this difference was not significant (Figure 2). However, the tests also showed that there was significant heterogeneity among the studies (I2 = 74.0%, P < 0.001). Heterogeneity in meta-analysis refers to the variation in study results between studies. To find out the source of heterogeneity, we conducted studies based on the following subgroups: type of patients (IBD, UC, CD, or IC), assessment method of 25OHD, and matching of the season for the control group. In the subgroup analysis, results remained non-significant, while the types of patients (IBD, UC, and CD) and assessment method of 25OHD were considered as possible sources of heterogeneity (Supplementary Figures 1–3).
Figure 2
Forest plot show the WMD in serum vitamin D concentrations between participants with IBD and healthy control.
The prevalence of vitamin D deficiency or insufficiency in patients with IBD was found as 44% (95% CI: 0.34–0.54) by eighteen studies with a total of 2,602 participants, with significant heterogeneity noted among studies (p < 0.001; I2 = 97.31%). The pooled prevalence of vitamin D deficiency or insufficiency in patients with IBD was 42% (95% CI: 0.29–0.56), UC was 51% (95% CI: 0.33–0.68), and CD was 42% (95% CI: 0.25–0.58) (Figure 3). In addition, the prevalence of participants with a level of vitamin D < 20 ng/ml was 41% (95% CI: 0.30–0.52) and the level of 20–30 ng/ml was 50% (95% CI: 0.32–0.69) (Figure 4).
Figure 3
Pooled estimate of the prevalence of vitamin D deficiency or insufficiency in children and adolescence with IBD, UC, and CD.
Figure 4
Pooled estimate of the prevalence of vitamin D status in children and adolescence with IBD.
Publication bias and sensitivity analysis
Evaluation of publication bias by visual inspection of the funnel plot and Egger's test demonstrated the evidence for publication bias in the meta-analysis of the prevalence of vitamin D deficiency or insufficiency in patients with IBD (p = 0.05) (Supplementary Figure 4). However, the results of the meta-trim-and-fill analysis found no studies. Egger's linear regression test for case-control studies revealed no publication bias (p = 0.31) (Supplementary Figure 5). Sensitivity analysis revealed that removing some of the studies would not have a significant impact on the overall results (Supplementary Figures 6, 7).
Discussion
This systematic review and meta-analysis were conducted using 35 articles. Our study results showed that vitamin D is deficient in children with IBD when compared to the healthy control group. But the results were not statistically significant. These results were similar to another study. A meta-analysis was conducted, including 14 studies of 1,891 patients, and reported that patients with IBD had more vitamin D deficiency when compared to controls, and the results were statistically significant (18). Vitamin D regulates cytokine secretion, which is involved in the inflammatory response in immune systems (45). Many studies that were conducted previously have reported that the levels of vitamin D are lower in children with IBD (23, 46). Even there are contradictory results regarding the association of vitamin D with IBD (15). Sufficient vitamin D has been associated with clinical benefits in children with IBD. There was a reduction in disease activity in children with sufficient vitamin D (41). Guzman-Prado et al. also showed that vitamin D supplementation in patients with IBD and vitamin D deficiency is effective at correcting vitamin D levels and is associated with improvements in clinical and biochemical disease activity scores (47).
The subgroup analysis of our study did not reveal a statistically significant deficiency in vitamin D concentrations. The same results were obtained in a study conducted by Kim (41). El-Matary et al. (23) reported that the levels of vitamin D were lower in children with UC, but it was not statistically significant. Another study reported that the levels of vitamin D were higher in children with CD, and it was statistically significant (48). Sensitivity analysis revealed that removing some of the studies would not have a significant impact on the overall results. The quality of all the studies was assessed using the Newcastle-Ottawa scale.
The scientific evidence on the role of vitamin D in children with IBD was reviewed by studies conducted previously (6, 49–51). Although, the effective vitamin D supplementation in children with IBD remains controversial. Our meta-analysis evaluating vitamin D status in 2602 participants, a large cohort population, would provide consistent and useful results.
A low level of vitamin D is clinically significant. Both UC and CD are related to environmental factors (52). Hypovitaminosis D in IBD is related to malabsorption, which may be due to inflammation in the bowel or surgical resection (12); less exposure to sunlight (50); and higher intake of vitamin D by the inflammatory cells (53).
In our study, the prevalence of vitamin D deficiency or insufficiency in patients with IBD was 44%. The pooled prevalence of vitamin D deficiency or insufficiency in patients with IBD was 42%, UC was 51%, and CD was 42%. In addition, the prevalence of participants with a level of vitamin D of < 20 ng/ml was 41% and the level of vitamin D of 20–30 ng/ml was 50%. Our study results confirmed prior study findings that reported a high prevalence of vitamin D deficiency in IBD (13, 29).
There are a few major strengths of the present systematic review and meta-analysis. First, a large number of studies were included, which provided a large sample size. In addition, we successfully pooled the results of subgroup analyses, sensitivity analyses, and publication bias. Similarly, there are some limitations in our study that should be considered. First, there existed a substantial degree of heterogeneity in the designs of studies, with a wide range of methods of vitamin D assessment. Nonetheless, we performed subgroup analysis to find possible sources of heterogeneity. Another important limitation of this study is that we could not identify the relationship between the season of vitamin D level measurement and IBD because many studies did not report this variable well.
Conclusion
This systematic review and meta-analysis study showed that patients with IBD were associated with vitamin D deficiency. Longitudinal studies should be conducted in the future to confirm our findings. Large randomized controlled trials assessing the doses of vitamin D supplementation would provide a better understanding of the association between vitamin D and IBD.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
SF, NAly, NAlb, FM, and MS contributed to the conception, design, and statistical analysis. SF, KP, NAly, NAlb, FM, PR, NK, AH, and AS contributed to data collection and the manuscript draft. AS, AH, and AA-Z supervised the study. All authors contributed the manuscript draft, critical revision, and approved the final version of the manuscript.
Funding
This article is taken from the disease registry, titled Registration of inflammatory bowel diseases in children and with code number IR.SBMU.RETECH.REC.1397.1199 from the ethics committee, which was supported by the deputy of research and technology at Shahid Beheshti University of Medical Sciences (http://dregistry.sbmu.ac.ir).
Acknowledgments
We express our gratitude to the participants of this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.1007725/full#supplementary-material
References
1.
BurischJMunkholmP. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. (2013) 29:357–62. 10.1097/MOG.0b013e32836229fb
2.
YeYManneSTreemWRBennettD. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. (2020) 26:619–25. 10.1093/ibd/izz182
3.
RuelJRuaneDMehandruSGower-RousseauCColombelJ-FIBD. across the age spectrum—is it the same disease?Nat Rev Gastroenterol Hepatol. (2014) 11:88–98. 10.1038/nrgastro.2013.240
4.
Gower-RousseauCVasseurFFumeryMSavoyeGSalleronJDauchetLet al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Digest Liver Dis. (2013) 45:89–94. 10.1016/j.dld.2012.09.005
5.
AnanthakrishnanAN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. (2015) 60:290–8. 10.1007/s10620-014-3350-9
6.
CantornaMTMunsickCBemissCMahonBD. 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. (2000) 130:2648–52. 10.1093/jn/130.11.2648
7.
Di RosaMMalaguarneraGDe GregorioCPalumboMNunnariGMalaguarneraL. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol. (2012) 280:36–43. 10.1016/j.cellimm.2012.10.009
8.
LagishettyVMisharinAVLiuNQLisseTSChunRFOuyangYet al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. (2010) 151:2423–32. 10.1210/en.2010-0089
9.
HewisonM. Vitamin D and immune function: an overview. Proc Nutr Soc. (2012) 71:50–61. 10.1017/S0029665111001650
10.
ZhaoHZhangHWuHLiHLiuLGuoJet al. Protective role of 1, 25 (OH) 2vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. (2012) 12:1–14. 10.1186/1471-230X-12-57
11.
AbrahamBPPrasadPMalatyHM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci. (2014) 59:1878–84. 10.1007/s10620-014-3102-x
12.
FarrayeFNimitphongHStucchiADendrinosKBoulangerAVijjeswarapuAet al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis. (2011) 17:2116–21. 10.1002/ibd.21595
13.
BruynJRPonsioenCYBrinkGRvdLöwenbergMBredenoordAJet al. Vitamin D deficiency in Crohn's disease and healthy controls: a prospective case–control study in the Netherlands. J Crohn's Colitis. (2014) 8:1267–73. 10.1016/j.crohns.2014.03.004
14.
JørgensenSPHvasCLAgnholtJChristensenLAHeickendorffLDahlerupJF. Active Crohn's disease is associated with low vitamin D levels. J Crohn's Colitis. (2013) 7:e407–e13. 10.1016/j.crohns.2013.01.012
15.
AlkhouriRHHashmiHBakerRDGelfondDBakerSS. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. (2013) 56:89–92. 10.1097/MPG.0b013e31826a105d
16.
VeitLEMarandaLFongJNwosuBU. The vitamin D status in inflammatory bowel disease. PLoS ONE. (2014) 9:e101583. 10.1371/journal.pone.0101583
17.
HarriesABrownRHeatleyRWilliamsLWoodheadSRhodesJ. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut. (1985) 26:1197–203. 10.1136/gut.26.11.1197
18.
Del PintoRPietropaoliDChandarAKFerriCCominelliF. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis. (2015) 21:2708–17. 10.1097/MIB.0000000000000546
19.
SelçukAAA. guide for systematic reviews: PRISMA. Turkish Arch Otorhinolaryngol. (2019) 57:57. 10.5152/tao.2019.4058
20.
BrookeBSSchwartzTAPawlikTMMOOSE. reporting guidelines for meta-analyses of observational studies. JAMA Surg. (2021) 156:787–8. 10.1001/jamasurg.2021.0522
21.
MargulisAVPladevallMRiera-GuardiaNVaras-LorenzoCHazellLBerkmanNDet al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa scale and the RTI item bank. Clin Epidemiol. (2014) 6:359. 10.2147/CLEP.S66677
22.
NwosuBUMarandaL. Vitamin D status and adiposity in pediatric malabsorption syndromes. Digestion. (2010) 92:1–7. 10.1159/000381895
23.
El-MataryWSikoraSSpadyD. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. (2011) 56:825–9. 10.1007/s10620-010-1380-5
24.
LaaksoSValtaHVerkasaloMToiviainen-SaloSViljakainenHMäkitieO. Impaired bone health in inflammatory bowel disease: a case–control study in 80 pediatric patients. Calcif Tissue Int. (2012) 91:121–30. 10.1007/s00223-012-9617-2
25.
ProsnitzARLeonardMBShultsJZemelBSHollisBWDensonLAet al. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease. Inflamm Bowel Dis. (2013) 19:45–53. 10.1002/ibd.22969
26.
ThorsenSUJakobsenCCohenALundqvistMThygesenLCPipperCet al. Perinatal vitamin D levels are not associated with later risk of developing pediatric-onset inflammatory bowel disease: a Danish case-cohort study. Scand J Gastroenterol. (2016) 51:927–33. 10.3109/00365521.2016.1144218
27.
SohnJChangEJYangHR. Vitamin D status and bone mineral density in children with inflammatory bowel disease compared to those with functional abdominal pain. J Korean Med Sci. (2017) 32:961–7. 10.3346/jkms.2017.32.6.961
28.
StrisciuglioCCenniSGiuglianoFPMieleECirilloGMartinelliMet al. The role of Inflammation on Vitamin D levels in a cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. (2018) 67:501–6. 10.1097/MPG.0000000000002049
29.
SentongoTASemaeoEJStettlerNPiccoliDAStallingsVAZemelBS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr. (2002) 76:1077–81. 10.1093/ajcn/76.5.1077
30.
PappaHMGrandRJGordonCM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis. (2006) 12:1162–74. 10.1097/01.mib.0000236929.74040.b0
31.
SalehiVSmallLYauMSockolowR. Vitamin D deficiency and abnormal bone density in pediatric patients with Inflammatory Bowel Disease. Inflam Bowel Dis. (2011) 17:S61–S. 10.1097/00054725-201112002-00194
32.
LevinADWadheraVLeachSTWoodheadHJLembergDACzarina Mendoza-CruzAet al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci. (2011) 56:830–6. 10.1007/s10620-010-1544-3
33.
GoldbergLYauMSalehiVSockolowREWardMJAntalZ. Small bowel disease in children and adolescents with inflammatory bowel disease is associated with deteriorating vitamin D status. Gastroenterology. (2012) 142:S370–S1. 10.1016/S0016-5085(12)61399-7
34.
SchaeferMFalaiyeT. Monitoring Vitamin D levels in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis. (2016) 22:S73–S4. 10.1097/01.MIB.0000480336.60576.4b
35.
SyedSSmithEMTangprichaVChesdachaiSKumarAPrinceJet al. Assessing the relationship of vitamin D with iron status in children with inflammatory bowel disease. Faseb J. (2016) 30:128–7.
36.
SyedSMichalskiESTangprichaVChesdachaiSKumarAPrinceJet al. Vitamin D status is associated with hepcidin and hemoglobin concentrations in children with inflammatory bowel disease. Inflamm Bowel Dis. (2017) 23:1650–8. 10.1097/MIB.0000000000001178
37.
BrandvaymanYRinawiFShamirRAssaA. Associations of seasonal patterns and vitamin D levels with onset and flares of pediatric inflammatory bowel disease. Minerva Pediatr. (2017) 73:42–49. 10.23736/S2724-5276.17.04847-2
38.
WinterRWLucciMBCollinsECaoBCarrellasMCrowellAMet al. Higher 25-Hydroxyvitamin D levels are associated with a greater likelihood of remission with anti-tumor necrosis factor-alpha medications among patients with inflammatory bowel diseases. Gastroenterology. (2015) 148:S249–S. 10.1016/S0016-5085(15)30819-2
39.
SauerCGLoopMSVenkateswaranSTangprichaVZieglerTRDhawanAet al. Free and bioavailable 25-hydroxyvitamin D concentrations are associated with disease activity in pediatric patients with newly diagnosed treatment naive ulcerative colitis. Inflamm Bowel Dis. (2018) 24:641–50. 10.1093/ibd/izx052
40.
MagerDRCarrollMWWineESiminoskiKMacDonaldKKlutheCLet al. Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur J Clin Nutr. (2018) 72:623–6. 10.1038/s41430-018-0105-2
41.
KimSKangYParkSKohHKimS. Association of Vitamin D with inflammatory bowel disease activity in pediatric patients. J Korean Med Sci. (2019) 34:e204. 10.3346/jkms.2019.34.e204
42.
VeitLEMarandaLNwosuBU. The nondietary determinants of vitamin D status in pediatric inflammatory bowel disease. Nutrition. (2015) 31:994–9. 10.1016/j.nut.2015.03.010
43.
SantucciNRAlkhouriRHBakerRDBakerSS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. (2014) 59:455–7. 10.1097/MPG.0000000000000477
44.
StrisciuglioCCenniSGiuglianoFPErasmoMCirilloGMartinelliMet al. The role of inflammation on vitamin D axis in a cohort of pediatric patients with inflammatory bowel disease. Digestive Liver Dis. (2017) 49:E260–E. 10.1016/j.dld.2017.09.050
45.
UlitskyAAnanthakrishnanANNaikASkarosSZadvornovaYBinionDGet al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J Parenteral Enteral Nutr. (2011) 35:308–16. 10.1177/0148607110381267
46.
BernsteinCNBlanchardJFLeslieWWajdaAYuBN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. (2000) 133:795–9. 10.7326/0003-4819-133-10-200011210-00012
47.
Guzman-PradoYSamsonOSegalJPLimdiJKHayeeBH. Vitamin D therapy in adults with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. (2020) 26:1819–30. 10.1093/ibd/izaa087
48.
Raffner BassonASwartRJordaanEMazinuMWatermeyerG. Vitamin D deficiency increases the risk for moderate to severe disease activity in Crohn's disease patients in South Africa, measured by the Harvey Bradshaw index. J Am Coll Nutr. (2016) 35:163–74. 10.1080/07315724.2015.1039665
49.
MouliVPAnanthakrishnanAN. vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. (2014) 39:125–36. 10.1111/apt.12553
50.
PalmerMTWeaverCT. Linking vitamin d deficiency to inflammatory bowel disease. Inflamm Bowel Dis. (2013) 19:2245–56. 10.1097/MIB.0b013e31828a3b6f
51.
CantornaMT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys. (2012) 523:103–6. 10.1016/j.abb.2011.11.001
52.
MolodeckyNPanaccioneRGhoshSBarkemaHKaplanG. Alberta Inflammatory Bowel Disease Consortium Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis. (2011) 17:1792–9. 10.1002/ibd.21511
53.
AbreuMKantorovichVVasiliauskasEGruntmanisUMatukRDaigleKet al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1, 25-dihydroxyvitamin D and low bone mineral density. Gut. (2004) 53:1129–36. 10.1136/gut.2003.036657
Summary
Keywords
vitamin D, inflammatory bowel disease (IBD), children, systematic review, supplement
Citation
Fatahi S, Alyahyawi N, Albadawi N, Mardali F, Dara N, Sohouli MH, Prabahar K, Rohani P, Koushki N, Sayyari A, Hosseini AH and Abu-Zaid A (2023) The association between vitamin D status and inflammatory bowel disease among children and adolescents: A systematic review and meta-analysis. Front. Nutr. 9:1007725. doi: 10.3389/fnut.2022.1007725
Received
30 July 2022
Accepted
10 November 2022
Published
09 January 2023
Volume
9 - 2022
Edited by
Mihnea-Alexandru Găman, Carol Davila University of Medicine and Pharmacy, Romania
Reviewed by
Mohammad Amin Khazeei Tabari, Mazandaran University of Medical Sciences, Iran; Victor Daniel Miron, Carol Davila University of Medicine and Pharmacy, Romania; Veronica Mocanu, Grigore T. Popa University of Medicine and Pharmacy, Romania
Updates
Copyright
© 2023 Fatahi, Alyahyawi, Albadawi, Mardali, Dara, Sohouli, Prabahar, Rohani, Koushki, Sayyari, Hosseini and Abu-Zaid.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Aliakbar Sayyari drsayyari@hotmail.comAmir Hossein Hosseini amir1981hosseini@gmail.com
This article was submitted to Sport and Exercise Nutrition, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.